Genome&Company지놈앤컴퍼니
314130 · KOSDAQ · ₩314130 · 지놈앤컴퍼니
₩3,505▼ ₩135 (3.71%)End-of-day · Oct 30, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 54.5% | 54.5% | 56.5% | 28.4% | 39.7% | 82.9% |
| Operating margin | −119.3% | −118.9% | −87.2% | −385.4% | −408.3% | −7,997.2% |
| Net margin | −169.1% | −26.1% | −72.5% | −332.0% | −368.0% | −7,560.6% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −0.5% | −11.4% | +94.1% | +1.5% | +3,021.3% | — |
| Operating income growth | +0.2% | −20.8% | +56.1% | +4.2% | −59.4% | — |
| Net income growth | −543.4% | +68.0% | +57.6% | +8.4% | −51.9% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −46.5% | −8.3% | −36.3% | −59.4% | −54.6% | −36.8% |
| Return on assets | −32.2% | −5.3% | −17.4% | −30.2% | −36.7% | −26.2% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 51.3% | 26.6% | 48.7% | 42.8% | 14.9% | 21.0% |
| Net debt to equity | −47.3% | −14.8% | −48.6% | −54.2% | −47.5% | −27.0% |
| Current ratio | 231.3% | 228.9% | 308.4% | 343.8% | 1,049.4% | 832.3% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Genome&Company / 지놈앤컴퍼니 / 314130 / KRX:314130
Source: KRX statistical information